RT journal article
T1 Anticoagulantes de acción directa en el síndrome antifosfolípido. Revisión sistemática
A1 Girón Ortega, José Antonio
A1 Girón González, José Antonio
A2 Medicina
K1 Antiphospholipid syndrome
K1 Arterial thrombosis
K1 Venous thrombosis
K1 Direct oral anticoagulants
K1 Warfarin
K1 Acenocoumarol
K1 Secondary prevention
AB The objective of the systematic review is to analyze the efficacy of direct-acting oral anticoagulants (DOAC) in the prophylaxis of thrombosis in antiphospholipid syndrome (APS). We searched for clinical trials, cohort studies and meta-analyses published from January 1, 2012 to September 30, 2022. Articles that analyzed the efficacy of DOAC in the prevention of thrombosis recurrence, with or without comparison with antivitamin K (VKA) drugs, were selected. DOACs, specifically rivaroxaban and apixaban, were significantly less effective than VKAs in preventing recurrence of thrombosis in patients with APS and prior arterial thrombosis or the concomitant presence of two or three different antiphospholipid antibodies. The proportion of patients with severe bleeding as side effect are similar in those treated with DOAC and with VKA. The results argue against the use of DOAC in the treatment of patients with thrombotic APS.
PB ELSEVIER
SN 1578-8989
YR 2023
FD 2023
LK http://hdl.handle.net/10498/33873
UL http://hdl.handle.net/10498/33873
LA spa
DS Repositorio Institucional de la Universidad de Cádiz
RD 13-nov-2026